fashion -WSS

fashion

author：fashion 2025-10-01 22:57:37 - browse：14569

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Obesity now affects over 1 billion people worldwide, study finds

WSS

Roche drug slashes death risk in early

Is there really a nursing shortage in the U.S.?

International team creates first chimeric human

STAT Readout: Friday, Oct. 20 biotech updates

Roche drug slashes death risk in early

Biotech companies concerned about China biosecurity crackdown

hotspot

fashion

focus

The cancer drug shortage isn’t new — and neither are the solutions

Medical device lobby: We're tired of waiting on Medicare coverage

Alkermes shareholders re

STAT Summit: Meghan O’Rourke on making chronic illness visible

United colonoscopy coverage change 'may cost lives,' doctors say

Health tech investors get more selective as pandemic boom fades

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech companies concerned about China biosecurity crackdown

In Memoriam: Notable people who died in 2023

FogPharma raises $145 million in rare Series E round

focus

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

AstraZeneca loses challenge to Medicare drug price negotiation

Study on Amgen’s bispecific immunotherapy produces positive data

Why getting cancer drugs just got harder for rural patients

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Results on Novartis prostate cancer therapy could expand its use

knowledge

knowledge

hotspot

knowledge